

AquaBounty wins Gold Leaf Award for Best "Emerging Agriculture Company" from BIOTECanada

November 16, 2017

MAYNARD, Mass., Nov. 16, 2017 (GLOBE NEWSWIRE) -- AquaBounty Technologies, Inc. (NASDAQ:AQB), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NYSE:XON), has won the Gold Leaf Award – "Emerging Agriculture Company" from BIOTECanada, Canada's national biotechnology industry association.

Launched in 2001, the Gold Leaf awards are given annually to recognize both companies and individuals who have made significant contributions to the biotech industry in Canada. AquaBounty's nomination competed alongside numerous others, and selection criteria such as technology advances, business milestones, and contribution to the Canadian biotech landscape were evaluated by a voting panel of industry peers. BIOTECanada presented AquaBounty with the Gold Leaf Award for Emerging Agriculture Company during the PEI BioAlliance kick-off to Global Biotech Week in Charlottetown, PEI.

Ronald Stotish, Chief Executive Officer of AquaBounty, stated: "Recognition from our industry peers is very welcome and much appreciated. Our efforts in Canada have been greatly aided by the business development environment, in particular the support of BIOTECanada and the PEI BioAlliance, as well as the support of provincial and national governments. These are exciting times for our company, and we look forward to the future as we grow our business, increase our workforce, and expand our contribution to the economy."

AquaBounty Management Team



AquaBounty Management Team Receiving Gold Leaf Award Front row, L to R: Chantal March, Dawn Runighan, Laura Braden, Ron Stotish, CEO, Rory Francis-PEI BioAlliance Back row, L to R: Dave Conley, Mark Walton, Andrew Casey-BIOTECanada AquaBounty Technologies, Inc.

"The Canadian biotech industry is linked from coast to coast by regional expertise comprised of universities, incubators, individual entrepreneurs, pre-commercial companies, multinationals, and investors all working to drive biotech solutions forward," commented Andrew Casey, President and CEO BIOTECanada. "AquaBounty highlights the particular strengths of the Canadian ecosystem, where game-changing innovations are being developed and supported by a community of entrepreneurs and leaders in all parts of the country."

AquaBounty is currently constructing a new 250-metric ton commercial production facility and a new broodstock facility in Rollo Bay, PEI, and renovating the former Bell Fish Company's 1200-metric ton production facility in Albany, Indiana, which it purchased in June this year.

Notes to Editors

Emerging Agriculture Company - AquaBounty

With depleted wild fish stocks, aquaculture production is meeting an increasing demand for nutritious food and animal protein, with the increasing production of salmon, tilapia and catfish, among other species. The future rising demand for fish as food will have to be met by increasing aquaculture production. Like the revolution in the application of new technologies to land-based food production over the past century, technology innovation is fueling the growth of the global aquaculture industry.

AquaBounty Technologies, Inc. is a publicly traded aquaculture company focused on improving productivity in commercial aquaculture. The Company's objective is the application of biotechnology to ensure the availability of high quality seafood to meet global consumer demand - addressing critical production constraints in the most popular farmed species, including salmon, trout, and tilapia.

Its AquAdvantage[®] fish program is based upon a single, specific molecular modification in fish that results in more rapid growth in early development. The aquaculture facility is located in eastern Prince Edward Island, AquaBounty is raising its disease-free, antibiotic-free salmon away from the ocean, thus eliminating the risk of escapes impacting native fish populations and the risk of pollutants or contaminants harming marine ecosystems.

In November 2015, AquaBounty announced that the U.S. FDA approved the Company's New Animal Drug Application for the production, sale, and consumption of its AquAdvantage[®] Salmon - a game-changer that will bring healthy and nutritious food to consumers in an environmentally responsible manner without damaging the ocean and other marine habitats.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding potential growth of the Company's business, increase in workforce, or expansion of economic contributions; the potential for renovation of the Company's production facility in Indiana and construction of production and broodstock buildings in Rollo Bay; and expected production capacities of the Company's facilities. Forward-looking statements may be identified with words such

as "will," "may," "expect," "plan," "anticipate," "upcoming," "believe," "estimate," or similar terminology, and the negative of these terms. Forward-looking statements are not promises or guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements. For additional information regarding these and other risks faced by us, please refer to our public filings with the Securities and Exchange Commission ("SEC"), available on the Investors section of our website at www.aquabounty.com and on the SEC's website at www.sec.gov.